Nina Bukhtiyarova

Nina Bukhtiyarova


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
OPOlena Popazova
Olena Popazova
IBIgor Belenichev
Igor Belenichev
NBNina Bukhtiyarova
Nina Bukhtiyarova
Viсtor RyzhenkoViсtor Ryzhenko
Viсtor Ryzhenko
NGNadia Gorchakova
Nadia Gorchakova
Oleksandr KamyshnyiOleksandr Kamyshnyi
Oleksandr Kamyshnyi
Prenatal hypoxia (PH) adversely affects the development of the fetal heart, contributing to persistent cardiovascular impairments in postnatal life. A key component in regulating cardiac physiology is the nitric oxide (NO) system, which influences vascular tone, myocardial contractility, and endothelial integrity during development. Exposure to PH disrupts NO-related signaling pathways, leading to endothelial dysfunction, mitochondrial damage, and an escalation of oxidative stress—all of which exacerbate cardiac injury and trigger cardiomyocyte apoptosis. The excessive generation of reactive nitrogen species drives nitrosative stress, thereby intensifying inflammatory processes and cellular injury. In addition, the interplay between NO and hypoxia-inducible factor (HIF) shapes adaptive responses to PH. NO also modulates the synthesis of heat shock protein 70 (HSP70), a critical factor in cellular defense against stress. This review emphasizes the involvement of NO in cardiovascular injury caused by PH and examines the cardioprotective potential of NO modulators—Angiolin, Thiotriazoline, Mildronate, and L-arginine—as prospective therapeutic agents. These agents reduce oxidative stress, enhance endothelial performance, and alleviate the detrimental effects of PH on the heart, offering potential new strategies to prevent cardiovascular disorders in offspring subjected to prenatal hypoxia.

9 November 2022 in Biology and Life Sciences Forum
Verified
Conference Paper
Open access
PDF file
IBIgor Belenichev
Igor Belenichev
Olena Gennadiivna AliyevaOlena Gennadiivna Aliyeva
Olena Gennadiivna Aliyeva
NBNina Bukhtiyarova
Nina Bukhtiyarova
OPOlena Popazova
Olena Popazova
VRViktor P. Ryzhenko
Viktor P. Ryzhenko
The aim of this research was to analyze the neuroprotective action of drugs via an evidence-based approach to analyzing the expression of endogenous neuroprotection factors in various experimental models of cerebral ischemia in Wistar white rats (intracerebral hemorrhage, carotid artery occlusion, prenatal hypoxia) to further substantiate their use in the treatment of CNS damage. The experimental studies were carried out in accordance with the “Regulations on the Use of Animals in Biomedical Research” and the European Convention on the Protection of Animals Used for Scientific and Other Purposes. The experiment was approved by the Bioethics Committee of Zaporizhzhia State Medical University. In studies, it was found that pharmacotherapy of emerging mitochondrial disorders with modulators of HSP70 expression—Cerebrocurin (composition: neuropeptides, S-100 proteins, reelin, factor nerve growth (NGF)), Glutoredoxin, Tamoxifen, (S)-2,6-diaminohexanoic acid, 3-methyl-1,2,4-triazolyl-5-thioacetate significantly (p < 0.05) stimulates energy production in the brain. This is expressed in an increase in the content of a number of intermediates of energy metabolism (glucose, pyruvate, succinate, isocitrate, malate) in the brain tissue, as well as an increase in the activity of pentose phosphate shunt dehydrogenase. A significant (p < 0.05) decrease in the level of lactic acid in the brain indicates a decrease in the proportion of anaerobic glycolysis. The most pronounced energotropic effect was shown by cerebrocurin (150 µL/kg) and (S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate (50 mg/kg). On the 21st day of treatment of rats with cerebral ischemia, there was a gradual reduction in the severity between animals with simulated pathology and healthy rats, which is associated with actively recovering mitochondrial energy production and cerebral load in general. These changes in energy metabolism correlate with the normalization of the oxidant–antioxidant balance and the concentration of HSP70 and HSF-1a in the cytosol and mitochondria of the cerebral ischemia zone and are manifested in a significant (p < 0.05) decrease in ultrastructural disorders of mitochondria. The energy-tropic and mitoprotective effects of the studied drugs are associated with their ability to protect mitochondrial proteins from oxidative damage by increasing the concentration of HSP70, prolong the lifespan of HSF-1a, and activate alternative energy generation pathways.

25 September 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
Viсtor RyzhenkoViсtor Ryzhenko
Viсtor Ryzhenko
IBIgor Belenichev
Igor Belenichev
OPOlena Popazova
Olena Popazova
NBNina Bukhtiyarova
Nina Bukhtiyarova
SOSergiy Oliynyk
Sergiy Oliynyk
Oleksandr KamyshnyiOleksandr Kamyshnyi
Oleksandr Kamyshnyi
Background: The high prevalence of chronic heart failure (CHF) in industrialized countries, alongside its grave consequences—including increased mortality, disability, functional impairment, and reduced quality of life—underscores the urgent need to optimize core medical therapy. In this regard, metabolic cardioprotectants are of particular interest, as their action is aimed at interrupting or mitigating the cascade of adverse metabolic reactions and enhancing the compensatory and adaptive mechanisms of the heart. The aim of this study was to evaluate the effect of sulfur-containing pharmacological agents—namely, N-acetylcysteine (NAC), Heptral, Thiotriazoline, and Angiolin—on selected parameters of the NO and thiol-disulfide systems in the hearts of rats with experimental doxorubicin-induced CHF, followed by an assessment of their cardioprotective efficacy. Methods: CHF was modeled in 70 male Wistar rats weighing 180–190 g by intraperitoneal administration of doxorubicin at a cumulative dose of 15 mg/kg, divided into 6 injections over 14 days. The investigated drugs were administered intragastrically once daily as a suspension in 1% starch mucilage for 30 days following the 14-day doxorubicin protocol: Angiolin ([(S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate], 100 mg/kg), Thiotriazoline (morpholinium thiazotate, 100 mg/kg), NAC (100 mg/kg), Heptral (S-adenosylmethionine, 100 mg/kg), and Mildronate (250 mg/kg). In the rat myocardium, key components of the NO and thiol-disulfide systems—iNOS, eNOS, nitrotyrosine, stable NO metabolites, glutathione peroxidase-4 (GPX4), glutathione reductase (GR), reduced glutathione (GSH), and oxidized glutathione (GSSG)—were determined using enzyme-linked immunosorbent assay (ELISA), biochemical assays, and real-time PCR. In serum, cardio-specific biomarkers were measured, including the creatine kinase-MB isoenzyme (CK-MB), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble ST2 protein (sST2). Results: It was established that on day 45 following the 14-day doxorubicin administration, alongside a significant elevation in CK-MB, NT-proBNP, and sST2 levels (p < 0.05), there was a concurrent upregulation of iNOS mRNA expression, iNOS protein levels, and nitrotyrosine formation, accompanied by a downregulation of eNOS mRNA expression, eNOS protein levels, and stable NO metabolites (p < 0.05). Furthermore, heart tissue from CHF rats exhibited depletion of the glutathione pool within the thiol-disulfide system, characterized by decreased GPX4, GR, and GSH levels alongside increased GSSG concentrations (p < 0.05). Course administration of the test pharmacological agents to experimental animals post-CHF induction resulted in an improvement in the evaluated parameters of the coupled NO and thiol-disulfide systems, as well as overall cardioprotection. The study analysis demonstrated that Angiolin was statistically superior to Heptral and Mildronate, whereas Thiotriazoline and NAC outperformed Mildronate. Conclusions: These findings confirm the potential cardioprotection provided by modulators of the SH/NO system. Based on these results, further preclinical investigation of Angiolin as a promising cardioprotective agent for CHF is experimentally substantiated.

30 November 2023
Verified
Conference Paper
Open access
PDF file
IBIgor Belenichev
Igor Belenichev
Olena Gennadiivna AliyevaOlena Gennadiivna Aliyeva
Olena Gennadiivna Aliyeva
NBNina Bukhtiyarova
Nina Bukhtiyarova
OROlga Ryzhenko
Olga Ryzhenko
DSDmytro Skoryna
Dmytro Skoryna
Significant risk of side effects of drug therapy in newborns, especially in premature neonates, is associated with immaturity of a number of enzyme systems and biotransformation mechanisms and pharmacokinetic specificity. We consider the use of thiotriazoline), a drug licensed in Ukraine with proven hepatoprotective and cardioprotective activity and a high safety profile, for premature infants to reduce side effects of antibiotic therapy. The use of thiotriazoline in antibiotic therapy results in an increase in the concentration of eNOS in blood plasma and a decrease in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase and bilirubin in blood plasma. These results provide experimental support for the use of thiotriazoline to reduce the side effects of azithromycin therapy in newborns.